Hydrochlorothiazide for Kidney Stones

Hydrochlorothiazide (HCTZ) has been prescribed for decades to prevent calcium kidney stones from coming back, and you may still see it recommended in older guidelines and patient handouts. But the largest and most rigorous modern trial, published in the New England Journal of Medicine in 2023, found that HCTZ at standard doses did not significantly reduce stone recurrence compared to a placebo. That result has forced a serious rethinking of a practice that many urologists and nephrologists treated as settled science, and the conversation around thiazide diuretics for stone prevention is now more nuanced than it used to be.

How HCTZ Is Supposed to Prevent Stones

Most kidney stones are made of calcium, usually calcium oxalate. The logic behind HCTZ is straightforward: if too much calcium is spilling into the urine, reduce it. HCTZ blocks a sodium-chloride transporter in the kidney’s distal tubule. When sodium reabsorption at that site is disrupted, the body compensates by pulling more sodium and water back in an earlier part of the kidney (the proximal tubule), and calcium gets swept along with it. The net result is less calcium in the urine, which in theory lowers the chance that calcium-based crystals will form and grow into stones.

There is an important caveat to this mechanism. Research going back to the 1970s showed that the parathyroid glands have to be functioning for thiazides to reduce urinary calcium. In studies of people whose parathyroid glands had been removed, HCTZ did not lower urinary calcium at all, even though sodium losses were similar to those in people with working parathyroids.¹ Separate research confirmed that thiazides appear to enhance the action of parathyroid hormone on both the kidney and bone, meaning the drug does not work in isolation but rather amplifies a hormonal signal that is already present.² For the vast majority of stone formers who have normal parathyroid function, this is not a practical concern. But it does explain why HCTZ is not universally effective and why some patients respond less than expected.

What the Largest Modern Trial Found

The study that changed the conversation is the NOSTONE trial, a randomized, double-blind, placebo-controlled study of 416 adults with recurrent calcium kidney stones (at least two episodes in the previous ten years). Patients were assigned to receive either a placebo or HCTZ at one of three doses: 12.5 mg, 25 mg, or 50 mg daily. They were followed for a median of about three years.³

The results were striking. Stone recurrence happened in about 59% of the placebo group, 59% of the 12.5 mg group, 56% of the 25 mg group, and 49% of the 50 mg group. None of these differences reached statistical significance, and there was no clear dose-response relationship. Even the 50 mg group, which showed the lowest recurrence rate, had confidence intervals that overlapped with the placebo group. Meanwhile, side effects including low potassium, gout, new-onset diabetes, skin allergies, and elevated creatinine were more common in the HCTZ groups.⁴

A subsequent meta-analysis that pooled all available randomized placebo-controlled trials of thiazide monotherapy, including NOSTONE, reached a blunt conclusion: current trial evidence does not show that thiazide monotherapy is significantly better than placebo at preventing kidney stone recurrence. The authors advocated for restrictive use of thiazides in stone prevention going forward.⁵

Why Older Studies Told a Different Story

If you search the older medical literature, you will find trials from the 1980s and 1990s that reported dramatic reductions in stone recurrence with thiazides. So what changed? The older trials tended to be smaller, open-label (meaning neither the patients nor the doctors were blinded to who got the drug), and sometimes used higher thiazide doses. They also frequently combined thiazides with dietary changes or potassium citrate, making it hard to separate the effect of the thiazide from the effect of the co-interventions. Some lacked a true placebo group altogether.

The NOSTONE trial was designed to fix these problems. It was large, double-blind, and tested HCTZ alone against a genuine placebo. That design is more likely to reveal the true drug effect, stripped of placebo responses, observer bias, and the confounding effects of lifestyle changes that patients often adopt when they enter a clinical trial. The result was humbling for a drug that had been a first-line recommendation for decades. It did not necessarily mean that HCTZ cannot lower urinary calcium; it clearly can. But lowering urinary calcium and actually preventing stones are not the same thing, and the NOSTONE trial showed that the leap from one to the other may not hold as firmly as clinicians had assumed.

Chlorthalidone May Work Better

Chlorthalidone is a thiazide-like diuretic with a much longer duration of action than HCTZ. While HCTZ is active for roughly 6 to 12 hours, chlorthalidone lasts around 48 to 72 hours. That pharmacological difference may matter for urine chemistry, because the calcium-lowering effect of HCTZ can wear off between doses, leaving a significant portion of the day unprotected.

Head-to-head comparisons support this idea. In one study, patients taking chlorthalidone at 25 mg daily had about a 41% reduction in 24-hour urinary calcium, compared to only about a 21% reduction in patients on the same dose of HCTZ.⁶ A more recent study looking at 12-hour versus 24-hour urine collections found that chlorthalidone reduced urinary calcium in both halves of the day, while HCTZ failed to produce a significant reduction regardless of whether it was taken in the morning or evening.⁷

These findings raise an uncomfortable question: was the NOSTONE trial really a test of thiazides in general, or was it a test of the wrong thiazide? If chlorthalidone provides more consistent calcium reduction throughout the day, it might still prove effective at preventing stones even though HCTZ did not. No large, placebo-controlled trial of chlorthalidone for stone prevention has been completed yet, so the question remains open, but the urinary calcium data are suggestive enough that some stone specialists have already shifted their preference.

Combining Thiazides With Potassium Citrate

One of the problems with using a thiazide alone is that it can lower potassium levels, which in turn reduces urinary citrate. Citrate is a natural stone inhibitor: it binds calcium in the urine and keeps it from crystallizing. So a thiazide can paradoxically undermine one of the body’s built-in defenses against stones even while it reduces urinary calcium. This is where potassium citrate comes in.

Adding potassium citrate to thiazide therapy serves two purposes. It replaces the potassium the thiazide drains, and it directly boosts urinary citrate. In studies of patients who continued to form stones despite thiazide therapy, adding potassium citrate restored citrate to normal levels and led to a significant reduction in stone formation.⁸ Other research showed that potassium citrate kept urinary calcium low while raising urinary pH and citrate, which enhanced the thiazide’s ability to lower the chemical saturation levels that drive calcium oxalate crystal formation.⁹

A direct comparison between potassium citrate alone and HCTZ alone in patients with high urinary calcium found that both lowered urinary calcium by a similar amount after 12 months, with no significant difference between groups.¹⁰ That finding is worth noting, because potassium citrate carries fewer systemic side effects than HCTZ. The combination of the two, though, remains a common clinical strategy, and long-term studies have found that combined thiazide-citrate therapy does not lead to the chronic low-potassium or metabolic alkalosis that clinicians sometimes worry about.¹¹

Side Effects to Watch For

Even at the moderate doses used for stone prevention, HCTZ carries a real side-effect profile. The NOSTONE trial confirmed that compared to placebo, patients on HCTZ had higher rates of low potassium, gout, new-onset diabetes, skin reactions, and worsening kidney function.¹² A review of thiazide trials in stone formers found that serum uric acid rose in every study that measured it, which is consistent with the gout risk, while potassium dropped in most studies that tracked it.¹³

Adding amiloride, a potassium-sparing diuretic, to HCTZ is another way to manage the potassium issue. Research has shown that the combination reduces potassium loss compared to HCTZ alone and may slightly enhance the calcium-lowering effect.¹⁴ In practice, clinicians often pair a thiazide with either potassium citrate or amiloride depending on the patient’s full metabolic workup.

The metabolic effects add up over time. Thiazide diuretics can trigger increases in blood sugar and uric acid levels.¹⁵ For someone taking HCTZ solely for stone prevention (as opposed to blood pressure control, where the cardiovascular benefits clearly outweigh these risks), the calculus is less favorable, especially now that the stone-prevention benefit itself is in doubt.

The Skin Cancer Question

You may have seen warnings linking HCTZ to skin cancer. HCTZ is a known photosensitizer, meaning it makes skin more sensitive to ultraviolet light, and a series of observational studies from Europe raised alarms about an association with squamous cell carcinoma. A meta-analysis of these studies found that HCTZ use was associated with roughly double the odds of squamous cell carcinoma.¹⁶

However, the picture is less alarming than a doubled risk might sound. A large propensity-matched cohort study comparing HCTZ users to users of other diuretics found only a modestly higher rate of skin cancer overall, translating to about 0.05 extra diagnoses per 100 patient-years, a very small absolute increase.¹⁷ And a U.S.-based population study that accounted for individual risk factors including race and ethnicity found no consistent association between HCTZ and nonmelanoma skin cancer across different insurance cohorts.¹⁸ The European studies that drove initial concern tended to involve populations with lighter skin exposed to different UV patterns, and confounding by sun exposure was hard to rule out.

For stone patients who may be on the drug for years, this is still worth a conversation with a doctor, especially if you have fair skin, a history of skin cancer, or heavy sun exposure. But on balance, the skin cancer signal appears to be small in absolute terms and may not apply equally across all populations.

Thiazides in Children

Children can develop kidney stones too, and hypercalciuria (too much calcium in the urine) is a common finding in pediatric stone formers. HCTZ has been used off-label in this population, typically at lower doses scaled to body weight. A study of low-dose HCTZ (0.5 mg per kilogram per day) in children with idiopathic hypercalciuria found it safe and effective at controlling urinary calcium.¹⁹

But there is a catch. A study using a somewhat higher dose (1 mg/kg/day) for three months found that while urinary calcium dropped as expected (reaching its lowest point after two weeks, then gradually creeping back up), the children also developed unfavorable cholesterol changes: total cholesterol and LDL cholesterol rose, while HDL cholesterol dipped. The shift in the LDL-to-HDL ratio suggested an increase in cardiovascular risk markers.²⁰ Whether these lipid changes matter over the long term in children is unknown, but they highlight the need to weigh risks carefully before committing a child to chronic thiazide therapy.

The Bone Density Side Story

One often-cited bonus of thiazide therapy is that it may protect bone density. By reducing the amount of calcium lost in urine, thiazides theoretically keep more calcium available for bones. An earlier study of stone formers found that HCTZ at 50 mg daily was associated with a measurable improvement in bone mineral density as assessed by CT scan.²¹

But the post-hoc analysis of the NOSTONE trial told a different story. Over roughly three years, bone mineral density declined in all groups, including those on HCTZ, and there was no statistically significant difference between any HCTZ dose and placebo. The analysis was thorough enough to estimate that even in the best-case scenario, the maximum plausible effect of HCTZ on bone density was tiny. The researchers concluded there was a very low likelihood that HCTZ achieves a clinically meaningful bone benefit in stone-forming patients.²² If bone protection was part of the rationale for keeping you on HCTZ, this finding weakens that argument considerably.

Where This Leaves You

If your doctor prescribed HCTZ to prevent kidney stones before the NOSTONE results came out, you are in a common situation. Many patients are now having conversations about whether to continue. The evidence landscape has shifted enough that a recent review explicitly called for restrictive use of thiazides in stone prevention.²³ That does not mean you should stop the drug on your own. If you also have high blood pressure, HCTZ may still be pulling double duty. And if your 24-hour urine tests show a clear drop in calcium on the drug, your stone risk profile may genuinely be better, even if the average effect across a clinical trial was unimpressive.

The practical questions to raise with your urologist or nephrologist include whether chlorthalidone might be a better fit, whether potassium citrate alone or in combination deserves a try, and whether your specific metabolic workup (24-hour urine calcium, citrate, uric acid, and oxalate levels) suggests a tailored approach rather than a single-drug strategy. Stone prevention is fundamentally personalized: what matters is your urine chemistry, your stone composition, and your tolerance for side effects, not the average outcome of a drug across hundreds of patients with varying biology.

Cost and the Role of Conservative Measures

Kidney stone prevention does not have to start with a prescription. Increasing fluid intake, moderating sodium and animal protein, and getting adequate dietary calcium (paradoxically, too little dietary calcium increases stone risk by leaving more oxalate free in the gut to be absorbed) are the foundation of stone prevention for everyone. A cost-effectiveness analysis found that conservative treatment (primarily dietary and fluid measures) was far less expensive than drug therapies, at roughly a quarter of the annual cost, though it carried a higher stone recurrence rate.²⁴ Drug treatments lowered recurrence further, but the NOSTONE trial now calls into question how much of that additional benefit is real for HCTZ specifically.

For many people, the path forward involves starting with aggressive fluid and dietary changes, getting a 24-hour urine study to identify specific metabolic abnormalities, and then selectively adding medication only if the numbers point to a clear target. If high urinary calcium is the dominant problem and a thiazide is warranted, chlorthalidone or a thiazide combined with potassium citrate may offer a better risk-benefit tradeoff than HCTZ alone. If high oxalate or low citrate is the main issue, other interventions make more sense entirely. The era of reflexively prescribing HCTZ for every recurrent calcium stone former is drawing to a close, and a more individualized approach is taking its place.